Moderna (NASDAQ:MRNA) President Sells $8,373,539.52 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 39,224 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $213.48, for a total transaction of $8,373,539.52. Following the transaction, the president directly owned 1,599,258 shares in the company, valued at $341,409,597.84. The trade was a 2.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Thursday, October 15th, Stephen Hoge sold 39,145 shares of Moderna stock. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40.
• On Monday, September 14th, Stephen Hoge sold 40,294 shares of Moderna stock. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22.
• On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The stock was sold at an average price of $146.07, for a total transaction of $5,883,845.67.

Moderna Stock Down 7.8%

NASDAQ:MRNA traded down $18.49 on Friday, hitting $218.01. The stock had a trading volume of 21,331,755 shares, compared to its average volume of 12,344,437. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The stock has a market cap of $87.04 billion, a P/E ratio of -27.29 and a beta of 1.09. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $242.29. The firm’s fifty day simple moving average is $153.48 and its two-hundred day simple moving average is $89.98.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter last year, the firm earned ($2.13) EPS. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. Analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current year.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investor enthusiasm remains centered on Moderna’s upcoming personalized cancer-vaccine data, particularly melanoma results expected next week. The catalyst helped drive the recent rally and keeps the company’s oncology pipeline in focus. Moderna falls ahead of cancer vaccine data next week
• Positive Sentiment: Moderna and Merck’s earlier cancer-vaccine progress continues to support optimism about the companies’ oncology strategy, although additional development work is still required. Merck and Moderna cancer vaccine strategy
• Neutral Sentiment: Goldman Sachs raised its price target to $137 from $120 while retaining a Neutral rating. The increase acknowledges Moderna’s momentum, but the target remains well below the stock’s recent trading level. Goldman raises Moderna price target
• Negative Sentiment: After gaining sharply on cancer-vaccine expectations, Moderna is experiencing profit-taking as investors reassess whether the rally has moved ahead of near-term fundamentals. Analysts have highlighted the company’s continuing losses, negative free cash flow, and valuation sensitivity to successful pipeline execution. Moderna stock sinks as Wall Street turns cautious
• Negative Sentiment: The selloff is also affecting vaccine developers broadly, with Novavax under heavier pressure and other vaccine stocks weakening. This sector-wide risk reduction is adding to selling pressure on MRNA. Selloff hits vaccine makers

Analysts Set New Price Targets

A number of analysts recently commented on the company. Bradesco Corretora upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Loop Capital set a $135.00 price objective on Moderna in a research note on Wednesday, August 19th. Piper Sandler raised their target price on Moderna from $77.00 to $167.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Finally, Rothschild & Co Redburn lowered Moderna from a “neutral” rating to a “sell” rating and raised their target price for the company from $40.00 to $81.00 in a research report on Thursday, September 3rd. Seven equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average price target of $101.45.

Institutional Investors Weigh In On Moderna

A number of hedge funds have recently modified their holdings of MRNA. Pension & Wealth Management Advisors Inc. bought a new stake in shares of Moderna in the third quarter valued at $169,000. NFSG Corp lifted its position in shares of Moderna by 2,581.0% during the 3rd quarter. NFSG Corp now owns 5,362 shares of the company’s stock valued at $1,033,000 after buying an additional 5,162 shares during the last quarter. R2 Capital Strategies LLC purchased a new position in shares of Moderna during the 3rd quarter valued at $347,000. Cohen Klingenstein LLC purchased a new position in shares of Moderna during the 3rd quarter valued at $404,000. Finally, PFG Private Wealth Management LLC bought a new position in shares of Moderna during the 3rd quarter worth $473,000. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.